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3206 | Chem. Sci., 2016, 7, 3206–3214“sarsasapogenin-aglyconed”
timosaponins as novel Ab-lowering modulators of
amyloid precursor protein processing†
Lai-King Sy,a Chun-Nam Lok,a Juan-Yu Wang,a Yungen Liu,a Lu Cheng,a Pui-Ki Wan,a
Chi-Ting Leung,a Bei Cao,a Wai-Lun Kwong,a Raymond Chuen-Chung Changb
and Chi-Ming Che*a
The inhibition of amyloid b (Ab) peptide production is a key approach in the development of therapeutics for
the treatment of Alzheimer's disease (AD). We have identiﬁed that timosaponins consisting of
sarsasapogenin (SSG) as the aglycone can eﬀectively lower the production of Ab peptides and stimulate
neurite outgrowth in neuronal cell cultures. Structure–activity relationship studies revealed that the cis-
fused AB ring, 3b-conﬁguration, spiroketal F-ring and 25S-conﬁguration of SSG are the essential
structural features responsible for the Ab-lowering eﬀects and neurite-stimulatory activity. New synthetic
derivatives that retain the SSG scaﬀold also exhibited an Ab lowering eﬀect. Treatment of cells with
timosaponins led to modulation of amyloid precursor protein (APP) processing through the suppression
of b-cleavage and preferential lowering of the production of the 42-amino acid Ab species (Ab42)
without aﬀecting another g-secretase substrate. The SSG and “SSG-aglyconed” timosaponins also
penetrated brain tissue and lowered brain Ab42 levels in mice. Our studies demonstrate that
timosaponins represent a unique class of steroidal saponins that may be useful for the development of
AD therapeutics.Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder that
starts with a decline in short-term memory and progresses to
the loss of cognition and executive functions. The pathology of
AD is characterized by synaptic loss, neuronal death, frequent
deposition of phosphorylated tau proteins and Ab aggregation
within the brain.1 Although the underlying cause of AD is
complex, the accumulation of Ab within the brain appears to
play a pivotal role in the onset and progression of the disease.2
Ab is generated from the proteolysis of amyloid precursor
protein (APP) during aging or in subjects with an inherited cause
of AD.3 APP is a transmembrane protein whose proteolysis is
mediated by a-, b- and g-secretases that cleave APP at specic
sites.3 The amyloidogenic process rst involves the cleavage ofof Hong Kong, Chemical Biology Centre,
or Interdisciplinary Research, 5, Sassoon
il: cmche@hku.hk; Fax: +852-28571586;
ool of Biomedical Sciences, LKS Faculty of
and Hormone, and Healthy Aging, LKS
of Brain and Cognitive Sciences, The
on (ESI) available: ESI includes
nd chemistry experiments, synthetic
analysis. See DOI: 10.1039/c5sc02377gAPP to create a c-terminal fragment (CTF), known as b-CTF,
which is subsequently cleaved by a multiprotein g-secretase
complex to produce diﬀerent lengths of Ab peptides such as
Ab38, Ab40 and Ab42. Genetic and mechanistic data strongly
suggest that the accumulation of amyloidogenic Ab42 peptide
results in the formation of toxic oligomers and/or brils.
Accordingly, Ab42-lowering compounds that target the b- and/or
g-cleavage processes represent a promising strategy for thera-
peutic intervention in AD.4,5 g-Secretase inhibitors (GSI) initially
emerged as eﬀective Ab-lowering agents, but the side eﬀects
resulting from non-specic inhibition of other vital g-secretase
substrates, such as Notch, have complicated the development of
these inhibitors.6With evidence for themore specic role of Ab42
in amyloidogenesis, current approaches to AD drug development
are focused on g-secretase modulators (GSM) that preferentially
lower Ab42 without aﬀecting the action of g-secretase on general
APP processing and the cleavage of other substrates.7 Modula-
tion of b-secretase is also considered to be a viable strategy for
lowering Ab production.8 A mutation in APP that hinders b-
cleavage and lowers the production of Ab by 40% was demon-
strated to be protective against AD and age-related cognitive
decline,9 supporting the idea that a moderate reduction of Ab in
humans is favourable for AD treatment or prevention.
Natural products provide opportunities for the development
of anti-AD pharmaceuticals (ESI Table S1†). For example, green
tea polyphenols, ginsenosides and resveratrol have all beenThis journal is © The Royal Society of Chemistry 2016
Fig. 1 Chemical structures of eﬀective Ab42-lowering agents in N2A-
APPswe cells.
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View Article Onlineshown to exhibit promising anti-amyloidogenic eﬀects.10–12 In
the course of studying the pharmacological properties of
medicinal saponins from natural products, we found that tim-
osaponins consisting of sarsasapogenin (SSG, 1) (Fig. 1) as the
aglycone, including timosaponin A III (TAIII, 2) isolated from
the rhizome of Anemarrhena asphodeloides Bge. (Liliaceae),
could eﬀectively lower Ab production. We have previously
identied TAIII's anti-cancer and autophagy-inducing proper-
ties.13,14 Oral administration of SSG, TAIII and other tim-
osaponins were shown to improve memory dysfunction in
animal models of dementia15–18 despite the chemical structural
diﬀerences between these compounds. Total saponins fromFig. 2 Chemical structures of SSG analogues.
This journal is © The Royal Society of Chemistry 2016Anemarrhena asphodeloides Bge. were reported to ameliorate
diabetes-associated cognitive decline in rats and mediate Ab
decreases in brain.19 In the present study, we show that SSG (1)
and other timosaponins (2–5, Fig. 1) specically exhibit Ab-
lowering activities and their actions are akin to GSM,7 which
preferentially lowers Ab42 peptide production. We propose
a model by which the timosaponins may bind to the steroid
binding site of APP,20 possibly modulating the APP secretase
properties. Importantly, SSG and several timosaponins showed
brain penetration and Ab42-diminishing activities in vivo.Results and discussion
Synthesis of timosaponins, SSG analogues and SSG derivatives
A. asphodeloides is a medicinal herb that is rich in structurally
closely related timosaponins whose isolation and purication
are exceptionally diﬃcult.17 Chemical synthesis, on the other
hand, is a feasible strategy to obtain timosaponins that are of
low natural abundance or commercially unavailable. Prepara-
tion of steroidal timosaponins (2–5) (Fig. 1) with diﬀerent sugar
lengths was achieved by reacting aglycone 1 with diﬀerent
glycosyl donors (ESI Fig. S1–S3†).
The chemical structure of the aglycone SSG (1) is rather
unique in naturally-occurring sapogenins due to its structural
characteristics, including a cis-fused AB ring (or 5b-congura-
tion), 3b-conguration, spiroketal F-ring and 25S-congura-
tion.21 In this study, a series of SSG analogues (6–24) (Fig. 2)Chem. Sci., 2016, 7, 3206–3214 | 3207
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View Article Onlinediﬀering in these structural features were employed to study the
structure–activity relationship (SAR) in the Ab-lowering activi-
ties. The linkage of AB rings in steroidal sapogenins can be cis-,
trans- or D5-double bonded. D5-Double bonded diosgenin (6)
and yamogenin (7) were studied in addition to “diosgenin-
aglyconed” saponins, including synthesized capsicoside A3 (8)
(ESI Fig. S4†), dioscin (9) and polyphyllin D (10). Hydrogenation
of saponins 9 and 10 generated AB ring trans-fused dihy-
drodioscin (11) and dihydropolyphyllin D (12), respectively (ESI
Fig. S5†). Similarly, hydrogenation of 6 and 7 produced AB ring
trans-fused tigogenin (13) and neotigogenin (14), respectively
(ESI Fig. S6†). Functionalization at D5 of 6 or D5 of 7 led to
production of a pair of isomers for each compound: 5a-H, 6a-
OH diosgenin (15), 5b-H, 6b-OH diosgenin (16) and 5a-H, 6a-
OH yamogenin (17), 5b-H, 6b-OH yamogenin (18) (ESI
Fig. S7†).22 The hydration products 15 and 17 are AB ring trans-
fused, while the new compounds 16 and 18 are AB ring cis-
fused.
Compound 1 has a secondary b-OH at C3. Oxidation of 1 to
sarsasapogenone (19) followed by reduction gave epis-
arsasapogenin (20) (ESI Fig. S8†).23
SSG 1 has heterocyclic rings E and F xed at C22 in which the
F-spiroketal ring appears to be a crucial moiety in bioactive
saponins21 (Fig. 2). Reductive cleavage of the F-ring in 1 gave
dihydrosarsasapogenin (dSSG, 21) with a terminal OH group24
(ESI Fig. S9†). Timosaponin B I (TBI, 22) and timosaponin B II
(TBII, 23) are two examples of “dSSG-aglyconed” saponins with
two sugar chains substituted at C3 and C26. The contribution of
the C25 S-conguration of 1 in decreasing Ab42 was also investi-
gated by comparing the activity of compound 16 and its epimer,
smilagenin (24), both of which have a C25 R-conguration.
We have synthesized new SSG derivatives (28–29, 32–34) in
an attempt to modify the biological activity and/or bioavail-
ability (Fig. 3).25,26 Reaction of 1 with propargyl bromide yieldedFig. 3 Synthesis of SSG derivatives. (i) Propargyl bromide, NaH, DMF, rt, 3
h, 63%; (iii) (a) MeOH-35% HCl (1 : 1), 40 C, 3 h; (b) 1 M HCl in MeOH,
CH2Cl2, 40 C, 3 h; (b) K2CO3, MeOH–H2O (5 : 1), reﬂux, 5 h; (c) HCl, 29:
HCl (1 : 1), 40 C, 3 h, 32: 24%; 33: 16%, 34: 38%. DMF ¼ dimethylformam
HOBt ¼ hydroxybenzotriazole.
3208 | Chem. Sci., 2016, 7, 3206–321425, containing a propargyl group, which can be linked to other
moieties or probes via click chemistry. By reacting 25 with
acetonide-protected a-galactose azide (26), via Cu(I)-catalysed
click chemistry, triazole SSG (27) was obtained. Removing the
acetonide protecting groups of 27 yielded a-OMe triazole SSG
(28) (ESI Fig. S10†). The relatively harsh reaction conditions
(strong base NaH and long reaction time) used in the prepara-
tion of 25 was also attempted for the preparation of carboxylate
ethereal SSG (29a) by reacting compound 1 with methyl bro-
moacetate, but without success. Compound 1 was then reacted
with diazoacetate, in the presence of Rh2(OAc)4 as a catalyst, to
obtain 29a in good yield via carbene insertion under mild
conditions. Hydroxylation of the carboxylate 29a in alkaline
conditions, followed by neutralization, produced the ethereal
SSG (29) (ESI Fig. S11†). The carboxylic acid of 29 serves as
a useful linkage for coupling with other moieties under mild
conditions. Reaction of 29 with acetonide-protected a-galactose
amine (30) gave amide SSG (31). The acetonide protecting
groups of 31 were then removed by acid hydrolysis to yield a-
OMe SSG (32), b-OMe SSG (33) and amixture of a- and b-OH SSG
(34) (ESI Fig. S12†).Ab42-lowering activities
Using Neuro-2A neuroblastoma cells stably transfected with
APP with the AD-linked Swedish mutation (N2A-APPswe) as
a cell culture model of Ab production,27 it was found that the
SSG 1 treatment modestly decreases Ab42 production with an
IC50 of 53 mM (Table 1). Treatment with timosaponins (2–5)
markedly lowered Ab42 production when compared to the
aglycone SSG. SSG analogue 18, in addition to the newly
synthesized SSG derivatives 28–29 and 32–34, also showed
slight to moderate improvement in Ab42-lowering activity when
compared to 1 (Table 1). In rat primary cortical neuronald, 46%; (ii) CuSO4$5H2O, ascorbic acid,
tBuOH/DMSO (4 : 1, v/v), rt, 24
rt, overnight, 58% (over 2 steps); (iv) (a) ethyl diazoacetate, Rh2(OAc)4,
80% (over 3 steps); (v) DIC, HOBt, CH2Cl2, rt, 48 h, 92%; (vi) MeOH-35%
ide; DMSO ¼ dimethyl sulfoxide; DIC ¼ N,N-diisopropylcarbodiimide;
This journal is © The Royal Society of Chemistry 2016
Table 1 IC50 values of timosaponins, SSG analogues and SSG derivatives in lowering Ab42 production in N2A-APPswe cells. Data represent mean
 standard deviation; n $ 3
Compound IC50 (mM) Compound IC50 (mM)
SSG (1) 53.0  9.0 5a-H, 6a-OH yamogenin (17) >100
TAIII (2) 2.3  0.2 5b-H, 6b-OH yamogenin (18) 45.0  4.0
TAI (3) 6.1  2.8 Sarsasapogenone (19) 50.0  5.0
TAV (4) 4.2  1.2 Episarsasapogenin (20) >100
AA (5) 6.0  1.4 Dihydrosarsasapogenin (21) >100
Diosgenin (6) >100 Timosaponin B I (22) >100
Yamogenin (7) >100 Timosaponin B II (23) >100
Capsicoside A3 (8) >100 Smilagenin (24) >100
Tigogenin (13) >100 a-OMe triazole SSG (28) 6.5  2.1
Neotigogenin (14) >100 Ethereal SSG (29) 27.0  8.0
5a-H, 6a-OH diosgenin (15) >100 a-OMe SSG (32) 7.2  2.2
5b-H, 6b-OH diosgenin (16) >100 b-OMe SSG (33) 9.3  3.5
a-, b-OH SSG (34) 7.3  4.0
Table 2 Eﬀects of SSG, TAIII and TAI on Ab42 levels in conditioned
medium of rat primary cortical neuron culture upon 5-day incubation.
A low concentration of SSG was used owing to the compound's
insolubility in the reduced serum medium for the neuronal culture.
Data represent mean  standard deviation; n ¼ 3
Compound Ab42 reduction (%)
SSG (1) (5 mM) 25  4
TAIII (2) (5 mM) 42  9
TAI (3) (10 mM) 28  5
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View Article Onlinecultures, which produce and secrete low levels of Ab, chronic
exposure to compounds 1–3 also resulted in a moderate
diminishment of Ab42 levels in the medium (Table 2).Structure–activity relationship
The role of the sugar chain in timosaponins. Treatment of
N2A-APPswe cells withmonosaccharide timosaponin A I (TAI, 3)
and disaccharide TAIII (2) showed an improved reduction of
Ab42 when compared to aglycone SSG 1 (Table 1), indicating that
the presence of the sugar chain is benecial in lowering Ab42
levels. However, trisaccharide timosaponin A V (TAV, 4), re-
ported for the rst time, showed no further lowering eﬀect (IC50
¼4.2 mM) when compared to disaccharide 2 (IC50¼2.3 mM).
In view of the importance of hydrophobicity to the cell perme-
ability of the compounds to be tested, timosaponins with longer
sugar chains were not considered in this study.28,29
Timosaponins 2–4 are galactosyl derived and exhibit prom-
inent Ab42-level reducing eﬀects. Asparagoside A (AA, 5), a glu-
cosyl-derived timosaponin (Fig. 1), shows a comparable Ab42-
lowering eﬀect (IC50 ¼ 6.0 mM) to galactosyl 3 (IC50 ¼ 6.1
mM), revealing that the nature of the monosaccharide coupled
to aglycone 1 has a negligible eﬀect on Ab42 levels.
The aforementioned enhancement in lowering Ab42
production by the sugar chains in timosaponins has not been
observed in the steroidal aglycone diosgenin 6 and its galactosyl
product 8 (Table 1). Taken together with the insignicant Ab42-This journal is © The Royal Society of Chemistry 2016lowering eﬀects exhibited by diosgenyl saponins (data not
shown) 9 and 10 (D5 double bond) and their corresponding
hydrogenated products 11 and 12 (both AB trans-fused rings), it
is suggested that aglycone 1 is critical in lowering Ab42
production. The structural features associated with 1, including
the AB-fused ring and the F-ring, were subjected to investigation
and the ndings are discussed below.
The roles of the AB-fused ring and the C3 conguration in
SSG. Diosgenin 6 and yamogenin 7, both having D5 double
bonds and diﬀerent congurations at C25 (R- for 6 and S- for 7),
showed no eﬀect in Ab42 lowering when compared to 1. Their
respective hydrogenated products 13 and 14, both of which have
AB rings trans-fused, were also ineﬀective (Table 1). In addition,
only compound 18 (AB rings cis-fused) from the 4 hydrated
products 15–18 caused reduction of Ab42 levels (Table 1), indi-
cating that the cis-fused AB ring (or 5b) in 1 is biologically
signicant in decreasing Ab42 production.
Compound 19, with a ketone functionality at C3, showed
a comparable eﬀect to 1 in Ab42 lowering, while compound 20,
with a C3 a-OH, was inactive (Table 1), implying that the 3a-
conguration is unfavourable for Ab42 lowering.
The roles of the F-spiroketal ring and the C25 conguration
in SSG. Steroidal sapogenins, including spirostane-, furostane-
and cholestane-types, are widely distributed in the plant
kingdom.30 SSG 1, which has an intact spiroketal F-ring, is an
example of the spirostane-type (Fig. 2). As mentioned above, this
compound exhibits an Ab42-lowering eﬀect. However, such an
eﬀect was not observed for the F-ring cleaved, furostane-type dSSG
21 (IC50 > 100 mM). In addition, timosaponin B I (22) and tim-
osaponin B II (23), possessing dSSG as the aglycone, are also
ineﬀective in lowering Ab42 (Table 1). Timosaponin B II (23),
however, has been shown to inhibit the up-regulation of b-secre-
tase induced by ferric chloride in rat retina.31 Ergosterol (structure
not shown) structurally resembles a cholestane-type aglycone.
This sterol also elicited no attenuation of Ab42 production (IC50 >
100 mM). It is therefore concluded that the F-spiroketal ring in 1
should remain intact for Ab42-lowering activity.
Smilagenin 24 and 6b-OH substituted 16 were ineﬀective in
lowering Ab42 (Fig. 2 and Table 1). Thus, one may envisage thatChem. Sci., 2016, 7, 3206–3214 | 3209
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View Article Onlinethe 25S-conguration in 1 is one of the vital structural factors
contributing to the compound's Ab-lowering activities.
Collectively, the SSG moiety is essential for Ab42-lowering
activity. Notably, the Ab42-lowering eﬀect of SSG is signicantly
enhanced when the compound is glycosylated at C3 to obtain
timosaponins 2–5 or carboxylated at C3 to obtain SSG deriva-
tives 28–29 and 32–34 (Fig. 1, 3 and Table 1). It is suggested that
chemical modication at the C3 position of 1 is an appealing
approach for the generation of versatile SSG derivatives with
anti-amyloidogenic eﬀects and thus timosaponins herein
represent a class of interesting saponins noteworthy of further
investigation related to Ab42-lowering activities.Fig. 5 Eﬀects of timosaponins and SSG on APP processing and Ab
proﬁles in N2A-APPswe cells. (A) Cells were treated with various
concentrations of TAIII/TAI/AA/TAV and DMSO vehicle as control (C)
for 18 h. The expression of full length (FL) and CTF in cell lysates and
the levels of secreted APP (sAPPa and sAPPb) in the conditioned
medium were examined by immunoblot. (B) The proﬁles of Ab42, Ab40
and Ab38 in the conditioned medium were determined by ELISA. (C)
Eﬀects of SSG on APP processing. (D) Eﬀects of SSG on Ab proﬁles.Biochemical mechanisms
Timosaponins modulate APP processing with suppression of
b-cleavage. We have investigated whether the timosaponins
interfere with APP processing by immunoblot analysis. Treat-
ment of N2A-APPswe cells with TAIII did not elicit a change in
the expression of full length APP, but resulted in the alteration
of the expression of the CTF and secreted APP fragments (sAPP)
(Fig. 4). In general, TAIII treatment decreased the levels of the b-
secretase-cleaved CTF (C-99) and secreted APPb in a concentra-
tion-dependent manner. Elevated concentrations (10 mM) of
TAIII increased the a-secretase-cleaved CTF (C-83) and secreted
APPa (Fig. 4). These changes in the expression of APP cleavage
products are indicative of suppression of the amyloidogenic
b cleavage and/or enhancement of the a cleavage, which is non-
amyloidogenic and is competitive to the former. Other tim-
osaponins (TAI/TAV/AA) that exhibited eﬀective Ab-lowering
activities also elicited changes in APP cleavage products similar
to that of TAIII (Fig. 5A). TAIII treatment did not aﬀect the
expression of the b-secretase BACE1 (Fig. 4), b-secretase activi-
ties in the cell extracts or the activities of puried BACE1.
Furthermore, TAIII treatment also did not alter the expressionFig. 4 Eﬀects of TAIII on Ab42 production and APP processing in N2A-
APPswe cells. Cells were treatedwith various concentrations of TAIII or
DMSO vehicle as control (C) for 18 h. (A) The Ab42 concentrations in
the conditioned medium were determined by ELISA. The cell viability
was determined by MTT assay. Data represent means  standard
deviation; n ¼ 3. (B) The expression of full length (FL), CTF (C99, C83),
BACE1 and ADAM10 (p: precursor form; c: cleaved form) in cell lysates
and secreted APP (sAPPa and sAPPb) in the conditioned medium were
examined by immunoblot.
3210 | Chem. Sci., 2016, 7, 3206–3214of ADAM-10, an a-secretase that is activated by proteolytic
cleavage (Fig. 4). Thus, these results suggest that the Ab-
lowering eﬀects mediated by timosaponins are unlikely to be
due to changes in the enzyme activities of a- and b-secretases.
However, allosteric modulation of the APP processing
complexes may be a possible cause for the alterations of APP
cleavage elicited by the timosaponins.
We also studied the eﬀect of SSG on the Ab production and
APP processing (Fig. 5C & D). The Ab-lowering activity of SSG
was weaker than those of timosaponins generally. Treatment of
N2A-APPswe cells with SSG at 50 mM and 100 mM for 18 h caused
a decrease in Ab42 by 55% and 40%, respectively. Interestingly,
treatment of cells with SSG at 100 mM increased both a-CTF and
b-CTF expression with marked increase in the sAPPa levels.
There was no change in b-secretase activity in the protein
extracts from SSG-treated cells compared to that from untreated
cells. Though the mechanism accounting for the diﬀerence
between timosaponins and SSG in APP processing remains to
be elucidated, it was concluded that the sugar moiety appears to
play a role in modifying the eﬀects of the timosaponins on APP
processing.
Timosaponins preferentially lower Ab42 production similar
to the action of GSM. Ab species of variable lengths are
generated upon cleavage of the CTFs of APP by g-secretase;
these Ab proles can be used for predicting the mechanisms of
action of drugs that act on the APP-secretase complexes.4,5 As
revealed by ELISA specic for individual Ab species, treatmentThis journal is © The Royal Society of Chemistry 2016
Fig. 7 Eﬀects of timosaponins and SSG on neurite outgrowth of
Neuro-2A cells. Cells were treated with DMSO (control), TAIII (5 mM),
TAI (10 mM), AA (10 mM), SSG (25 mM) and TAV (10 mM) for 18 h, stained
with a monoclonal antibody raised against type III b-tubulin and
examined by ﬂuorescence microscopy.
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View Article Onlineof cells with timosaponins (TAIII/TAI/TAV/AA) eﬀectively low-
ered the levels of secreted Ab42 while having a much smaller
eﬀect on Ab40 and Ab38 (Fig. 5B). The timosaponins' prefer-
ential eﬀects on Ab42, over the shorter forms of Ab species,
resemble the results of g-secretase modulation.4–7 Currently,
identication of novel GSM is of considerable interest in the
development of AD therapeutics, because Ab42 oligomers or
brils are considered to be the most toxic Ab species in AD
pathology.
GSM are expected to selectively act on the APP complexes,
without inhibiting the cleavage activity of g-secretase on other
physiological substrates.6,7 To further investigate the specicity
of the impact of timosaponins on g-secretase-mediated protein
processing, the eﬀects of timosaponins on the g-secretase-
mediated cleavage of the transmembrane receptor Notch1 were
examined (Fig. 6). g-Secretase-catalysed cleavage of Notch
releases the Notch intracellular domain (NICD), which regulates
developmental gene transcription.32 In cells expressing
a Notch1 variant containing transmembrane and intracellular
domains (NotchDE), the NICD is constitutively present due to g-
secretase activity (Fig. 6). Treatment of cells with a g-secretase
inhibitor DAPT completely blocked the production of NICD,
while treatment of cells with timosaponins at concentrations
that eﬀectively lower Ab levels did not aﬀect NICD levels. Thus,
the timosaponins selectively interfere with Ab production
without altering Notch1 processing.
Timosaponins stimulate neurite outgrowth. Intriguingly,
treatment of cells with SSG (1) and timosaponins (2–5) also
markedly stimulated neurite outgrowth at concentrations that
lower Ab production, as revealed by type III b-tubulin immu-
nostaining (Fig. 7). The neurite outgrowth stimulation was not
shared by other steroidal saponins (e.g., 8–12) or SSG analogues
(e.g., 6, 7, 13, 14, 20, and 24) investigated in this study. Stimu-
lation of neurite outgrowth is considered to be a favourable
property in pharmaceuticals designed to ameliorate AD, which
is characterized by neuronal loss.1 Neurite outgrowth is
a complex neuronal process that is, in part, modulated through
the interaction of membrane-bound and/or secreted forms
of APP with proteins of axonal and dendritic growth
machinery.33,34 The mechanism by which timosaponins exhibit
neurite outgrowth stimulatory property remains to be eluci-
dated, but is perhaps related to its APP modulating properties,
which may tip the balance toward neurite growth and
branching.Fig. 6 Eﬀects of timosaponins on Notch cleavage by g-secretase.
N2A-APPswe cells were transfected with myc-tagged NotchDE
construct, which is constitutively cleaved by g-secretase to generate
NICD. Cells were then treated with DMSO control (C); the indicated
concentrations of timosaponins or DAPT (as a positive control for g-
secretase inhibition) for 18 h and the expression of NotchDE and NICD
were examined by immunoblot analysis.
This journal is © The Royal Society of Chemistry 2016APP as a potential molecular target of timosaponins. Taken
together, our data demonstrate that timosaponins modulate
APP processing with a suppression of b-cleavage and selective
reduction in Ab42 production. To establish a possible binding
model of the molecular targeting of Ab, molecular simulation of
timosaponins to APP was performed. We postulate that tim-
osaponin binds to APP because there is evidence for interac-
tions between a number of GSM and APP, particularly at its
transmembrane region that contains the sites of g-cleavage
(Fig. 8A).35 We employed a model of an APP fragment (Protein
Data Bank ID: 2LP1) that spans the extracellular juxtamem-
brane and transmembrane domains (TMD) (Fig. 8). Previous
NMR analyses indicate that the extracellular amino terminus
includes a surface-embedded “N-helix” followed by a short “N-
loop” connecting to the TMD.20 Importantly, a binding pocket
for cholesterol, centred around the N-helix/N-loop/TMD struc-
tural element, has been identied (Fig. 8A).20 Our preliminary
molecular docking analysis revealed that SSG and timosaponins
can be positioned within the cholesterol binding pocket (ESI
Fig. S14†). High level hybrid quantum mechanics/molecular
mechanics (QM/MM) calculation (ESI†) was performed to
provide in depth understanding on the timosaponin binding to
the transmembrane domain of APP (Fig. 8B and C). The results
imply that the binding interaction is selective, which is probably
due to the specic polarity of the SSG-aglyconed timosaponins
(Fig. 8B and C). The parent SSG part of TAIII containing the
lipophilic steroid ring is surrounded by a group of hydrophobic
residues (689–692, 695, 696, 704, 705, 707–712), while the polar
part of TAIII possessing the hydrophilic galactose moiety is
surrounded by several polar residues (697–699) and lies at the
surface of the transmembrane. In particular, the binding pose
of the SSG motif is proximal to the GXXXG motifs (particularly,
the G700AIIG704) of the TMD. These motifs have been shown to
be important in the production of the long and short forms of
the Ab polypeptides mediated by g-secretase. In addition, these
motifs are involved in the non-steroidal anti-inammatory drug
(NSAID)-derived GSM modulation of g-secretase.36,37 Nonethe-
less, further experiments (e.g., crystallography) are needed to
validate the specic binding mode. It is noteworthy that theChem. Sci., 2016, 7, 3206–3214 | 3211
Fig. 8 APP transmembrane domain as a potential molecular target of
timosaponins. (A) An overview of the portion of APP that is cleaved by
a-, b-, and g-secretases. Also shown are the juxtamembrane and
transmembrane regions harbouring binding sites for NASID-like GSM34
and cholesterol.20Numbering is according to the full length of APP770.
(B) QM/MM calculations of TAIII binding to the transmembrane
domain of APP. The surface representation of the transmembrane
region of APP, showing the calculated binding pose of TAIII. (C) The
hydrophobic residues and polar residues around TAIII are portrayed
with stick display mode. Carbon atoms of hydrophobic residues are
highlighted in green and carbon atoms of polar residues are high-
lighted in light blue. TAIII is represented by sticks with the carbon
atoms in yellow. Colour code: carbon (yellow, green or light blue),
nitrogen (dark blue), oxygen (red), and hydrogen (white).
Fig. 9 In vivo Ab42-lowering activities of SSG and timosaponins. 3–5
month old C57BL/6micewere dosedwith vehicle (C), TAI, TAIII, SSG or
a-, b-OH SSG (34) at 100 mg kg1 by oral gavage for three times in 2
days. The levels of Ab42 in the mouse brain were determined by ELISA.
The number (n) of animals for vehicle control, TAI, TAIII and SSG ¼ 10;
for 34, n ¼ 6. Data represent means  standard deviations. Statistical
signiﬁcance in diﬀerences between vehicle control and treatment
groups was determined by Student's test, #, P < 0.1; *, P < 0.05.
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View Article Onlinemodulation of APP processing by some endogenous steroid-like
compounds from animals and plants has been recently
reported.38,39
In vivo Ab-lowering activities of timosaponins. The in vivo
Ab-lowering activities of timosaponins were examined in mice.
A group of 3–5 month old C57BL/6 mice was dosed with SSG (1),
TAIII (2), TAI (3) or a-, b-OH SSG (34) at 100 mg kg1 by oral3212 | Chem. Sci., 2016, 7, 3206–3214gavage for three times in 2 days. The results showed that these
compounds elicited a reduction of Ab42 levels in the brain (77%
 4% for SSG, P < 0.05; 83%  13% for TAIII, P < 0.05; 87% 
14% for TAI, P¼ 0.09; 87% 15% for 34; P¼ 0.09) (Fig. 9). Such
a moderate degree of Ab42 reduction has been demonstrated by
many Ab-lowering natural compounds (ESI Table S1†). We also
determined the levels of SSG 1, timosaponins 2–3, compound
34 and their metabolites in the plasma and brain of the mice by
ultra-performance liquid chromatography tandem mass spec-
trometry. The timosaponins and/or their deglycosylated prod-
ucts (TAI and SSG) at low micromolar concentrations could be
detected in the plasma and brain at the end of the experiments
(ESI Table S2†). No further metabolites except the deglycosy-
lated products (TAI, SSG from TAIII; SSG from TAI) were
detected. The reason for the scarcity of TAIII in the brain is
uncertain but may be attributed to a lower ability of the glyco-
sylated compounds to cross the blood brain barrier and/or an
elevated glycohydrolase activity in the neurons.40 Compound 34
was present at a much lower level in the mouse plasma and
brain compared to its closest analogue TAI, suggesting that the
nature of C3 linkage may have an impact on the bioavailability
and/or tissue distribution. Further pharmacokinetics studies of
SSG and the timosaponins and their derivatives are required to
elucidate the structural features of the timosaponins required
for optimal bioavailability and eﬃcacy. Collectively, our results
reveal that SSG and certain timosaponins display oral
bioavailability, brain penetration capacity and Ab-lowering
activity in vivo.Conclusion
The timosaponins investigated in the current study are prefer-
entially able to lower Ab42 production and stimulate neurite
outgrowth, largely due to the presence of the eﬀective aglycone
SSG 1. They contain structural features including a cis-fused AB
ring, 3b-conguration and an intact F-spiroketal ring with a 25S-
conguration. These characteristics are indispensableThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinestructural requirements for the compound's dual properties.
The Ab-lowering activities of “SSG-aglyconed” timosaponins are
generally associated with decreases in b-cleavage and/or
increases in a-cleavage of APP. These are accompanied by
a preferential reduction of Ab42 levels without aﬀecting the
processing of other g-secretase substrates, resembling the
action of GSM. Thus, the “SSG-aglyconed” timosaponins are
novel agents that modulate APP processing and subsequently
lower Ab production. We have also shown here that some tim-
osaponins and SSG exhibit Ab-lowering activities in vivo. It is
envisaged that, when properly modied and formulated, tim-
osaponins will be intriguing compounds for the development of
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